Scientists describe genetic program behind primordial lung progenitors

For the first time, researchers describe the genetic program behind primordial lung progenitors--embryonic cells that give rise to all the cells that form the lining of the respiratory system after birth.

They believe this study has long-term implications for the treatment of diseases affecting the respiratory system, such as chronic obstructive pulmonary disease (COPD), alpha-1 antitrypsin deficiency and cystic fibrosis.

Diseases affecting the lungs are not easily treatable and result in significant morbidity and mortality worldwide.

Specialized stem cells with the potential to self-renew have been proposed as a critical component of tissue homeostasis for many organs, including the lung. Similar cells can be engineered in vitro and used in the future in cell replacement therapies for respiratory diseases.

Using a genetically modified experimental model, researchers from the Center for Regenerative Medicine (CReM) of Boston University and Boston Medical Center, were able to isolate and describe the genetic program of the earliest lung progenitor cells and understand the signals that instruct them.

They then used computational methods that helped them define how similar their engineered lung cells are to the in vivo progenitors.

Our findings define in great detail a rare, transient cell, namely the primordial lung progenitor. The knowledge generated from this study will be of great value in the derivation of human primordial lung progenitors in culture, since the equivalent stage in human lung development is not accessible."

Laertis Ikonomou, PhD, Study Corresponding Author and Assistant Professor of Molecular and Translational Medicine, Boston University School of Medicine

Respiratory system diseases, such as COPD, cystic fibrosis and lung interstitial disease severely affect quality of life. "We hope that our findings will eventually lead to more protocols for, transplantable lung epithelial cells for treatment of such diseases and for drug development," added Ikonomou.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
How SARS-CoV-2 immune responses vary by population due to environmental and genetic factors